

Agatolimod

Cat. No.:	HY-146244
CAS No.:	525625-52-9
Molecular Weight:	7704
Sequence:	DNA, d(P-thio)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T)
Target:	Toll-like Receptor (TLR)
Pathway:	Immunology/Inflammation
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Agatolimod

SOLVENT & SOLUBILITY

In Vitro

H₂O : ≥ 125 mg/mL (16.23 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent	1 mg	5 mg	10 mg
	Concentration			
1 mM	Mass	0.1298 mL	0.6490 mL	1.2980 mL
5 mM	Mass	0.0260 mL	0.1298 mL	0.2596 mL
10 mM	Mass	0.0130 mL	0.0649 mL	0.1298 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Agatolimod (ODN 2006), a class B ODN (oligodeoxynucleotide), is a TLR9 agonist. Agatolimod is also an optimal CpG sequence for humans. Agatolimod stimulates very strong production of NO₂ and IL-6 in HD11 cells. Agatolimod can be used for breast cancer research. Sequence: 5'-tcgctgttttgcgttttgcgtt-3'^{[1][2]}.

IC₅₀ & Target

TLR9

REFERENCES

- [1]. Xie H, et al. CpG-induced immunomodulation and intracellular bacterial killing in a chicken macrophage cell line. *Dev Comp Immunol*. 2003 Oct;27(9):823-34.
- [2]. Babaer D, et al. Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells. *Cancers (Basel)*. 2019 May 14;11(5):672.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA